Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

Nair, Muraleedharan G.; Nampoory, M.R.N.; Johny, K.V.; Costandi, J.N; Abdulhalim, M; El-Reshaid, Wael; Al-Muzairai, I.; Ninan, V.T.; Samhan, M; Al-Mousawi, M

doi:10.1016/s0041-1345(01)02184-4

Cited by 31 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2). It has been shown that IL-2 levels are increased in patients after transplantation, and two IL-2 receptor antagonists are approved for clinical use in preventing acute rejection episodes after transplantation [26,27]. Our results that IL-2 is increased after ischemia is in agreement with this study and other studies which highlight the role of ROS-mediated activation of IL-2 and suggest that IL-2 promotes injury in IR [28].…”

Section: Discussionsupporting

confidence: 93%

MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In renal transplantation, a prospective trial comparing daclizumab (n=13) with basiliximab (n=10) found similar rates of ACR after 6 months and survival at 1 year. 15 However, a similar comparison in another study (basiliximab, n=30; daclizumab, n=28) found that 7 patients who received daclizumab had ACR at 6 months compared with no patients in the basiliximab group. 16 In addition, a large head-to-head comparison of basiliximab (n=107) and daclizumab (n=105) was performed in a randomized prospective analysis of deceased donor renal transplant recipients.…”

Section: Discussionmentioning

confidence: 85%

Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab

Martin

Kato

Farr

et al. 2015

Circ J

View full text Add to dashboard Cite

Background Induction therapy with interleukin-2 receptor antagonists has been established as an effective immunosuppressive strategy in the management of heart transplant (HTx) recipients. We compared outcomes following HTx in patients receiving basiliximab, daclizumab, or no induction therapy. Methods and Results We investigated post-transplant prognosis of patients receiving basiliximab (n=67), daclizumab (n=98) or no induction therapy (n=70). Patients treated with daclizumab (50.3±14.7 years) were younger than those receiving basiliximab (55.8±11.2 years) or no induction therapy (54.9±14.1 years; both P<0.05). Patients receiving either induction therapy showed better survival 1 year after HTx (95%) than those without induction therapy (82%; P<0.001). Survival was similar between patients receiving basiliximab and daclizumab. The incidence of acute cellular or antibody-mediated rejections did not differ among the groups. The main reason that patients did not receive induction therapy was ongoing infection (65.7%), which was more common in patients on ventricular assist device (VAD) support than those without VAD (76.1% vs. 45.8%; P=0.004). The VAD-related infection rate in the entire study cohort was 29.7% (35/118 VAD recipients). Conclusions Survival following HTx was worse in patients not receiving induction therapy. No differences were noted in survival or the incidence of rejection between the daclizumab- and basiliximab-treated groups. Induction therapy was less used in patients with infection, which was related to prior VAD support.

show abstract

“…Studies reporting adverse reactions associated with the use of daclizumab are presented in Table 25 . [279][280][281][282][283][284][285][286][287][288][289][290][291][292] Table 26 summarizes six studies using daclizumab for 298 This reaction has been observed on initial exposure and following reexposure to daclizumab. Patients may develop hypotension, bronchospasm, wheezing, laryngeal edema, pulmonary edema, cyanosis, hypoxia, respiratory arrest, cardiac arrhythmia, cardiac arrest, peripheral edema, loss of consciousness, fever, rash, urticaria, diaphoresis, pruritus, or injection site reactions.…”

Section: Daclizumabmentioning

confidence: 99%

“…203,279,280,282,284,285,[288][289][290][291][292][300][301][302][303] 3.4.2.2 Pediatrics-The safety and effi cacy of daclizumab have been described in pediatric renal, liver, and cardiac transplant studies 283,301,304,305 ; however, none are prospective, randomized trials. Proprietary studies in pediatric patients have established the safety of daclizumab in those aged 11 months to 17 years.…”

Section: Daclizumabmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

Cited by 31 publications

References 19 publications

MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury

MnTMPyP, a superoxide dismutase/catalase mimetic, decreases inflammatory indices in ischemic acute kidney injury

Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About